ivd medical products & reagents for blood bank : galileo, neo :analyzer, reagents, solutions, consumables and service parts
איילקס ביוטק בע"מ - מומחה - מערכות אוטומטיות ממוחשבות ומגיבים לעבודה ידנית לסיווג קבוצות דם וסקר נוגדנים הכוללות: מיכשור,מגיבים,בקרים ונלווים
נוקספיל תרחיף
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
נוקספיל תרחיף
merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
נוקספיל 100 מג טבליות עמידות בקיבה
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - posaconazole 100 mg - posaconazole
נוקספיל 300 מג תמיסה מרוכזת להכנת תמיסה לעירוי
merck sharp & dohme israel ltd - posaconazole - תרכיז להכנת תמיסה לאינפוזיה - posaconazole 300 mg/vial - posaconazole
קרסמבה 100 מג כמוסות
pfizer pfe pharmaceuticals israel ltd - isavuconazole as sulfate - קפסולה קשיחה - isavuconazole as sulfate 100 mg - isavuconazole
קרסמבה 200 מג תוך ורידי
pfizer pfe pharmaceuticals israel ltd - isavuconazole as sulfate - אבקה להכנת תמיסה מרוכזת לעירוי - isavuconazole as sulfate 200 mg - isavuconazole
סוטנט 12.5 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
סוטנט 25 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
סוטנט 50 מג
pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.